Abstract：
Shen chan decoction (SCD) as a significant Traditional Chinese medicine (TCM) to treat atopic dermatitis (AD), but its mechanism of action has not been clarified, so we started the present study, first possible effects of SCD on AD were predicted using network pharmacology. Next, dinitrochlorobenzene was used to establish a mouse model of AD. After successful modelling, the SCD were administered intragastrically to treat the mice. Eventually, the KEGG pathway enrichment analysis indicated that SCD improved AD mainly through effects on inflammation and the gut microbiota. The experimental findings revealed that SCD treatment attenuated AD symptoms and downregulate the characteristic immune factors, namely IL-4, IL-6 and IgE. Moreover, it promoted a balance between Th1/Th2 cells. Furthermore, the itch signaling pathways involving H1R/PAR-2/TRPV1 were inhibited. The 16S rRNA sequencing results indicated that SCD administration influenced the Firmicutes/Bacteroidetes ratio at the phylum level by augmenting the relative proportions of Lactobacillaceae and Muribaculaceae at the family and genus levels, while decreasing the abundances of Lactococcus and Ruminococcus. These findings suggest that internal administration of SCD is an effective therapeutic approach for AD. We suggest that SCD may be an alternative therapy for the treatment of AD.Additionally, it could offer valuable insights into the pathogenesis of AD and the development of innovative therapeutic agents.
摘要：
参禅汤作为治疗特应性皮炎(AD)的重要中药,但其作用机制尚未明确,所以我们开始了目前的研究，首先使用网络药理学预测SCD对AD的可能影响.接下来,二硝基氯苯用于建立AD小鼠模型。建模成功后,将SCD胃内给药以治疗小鼠。最终,KEGG途径富集分析表明,SCD主要通过对炎症和肠道菌群的影响来改善AD。实验结果表明，SCD治疗可以减轻AD症状并下调特征性免疫因子，即IL-4、IL-6和IgE。此外，它促进了Th1/Th2细胞之间的平衡。此外，涉及H1R/PAR-2/TRPV1的瘙痒信号通路被抑制。16SrRNA测序结果表明，SCD管理通过增加家族和属水平的乳杆菌和Muribaculaceae的相对比例，影响了门水平的Firmicutes/拟杆菌比例，同时降低乳球菌和反刍动物的丰度。这些发现表明SCD的内部给药是AD的有效治疗方法。我们建议SCD可能是治疗AD的替代疗法。此外,它可以为AD的发病机制和创新治疗剂的开发提供有价值的见解。
